帕利哌酮缓释片用于儿童期首发精神分裂症治疗临床研究.docVIP

精品论文 参考文献 帕利哌酮缓释片用于儿童期首发精神分裂症治疗临床研究 陆志新 张霞 石磊 李志佳 　　（无锡市精神卫生中心 江苏 无锡 214151） 　　【摘要】 目的：探讨将帕利哌酮缓释片用于治疗儿童期首发精神分裂症患的疗效及优缺点。方法：回顾性分析40例应用帕利哌酮缓释片治疗的儿童期首发精神分裂症患者临床资料，以其用药前后的病情进行自身对比，用药6个月后观察其疗效和不良反应。结果：至用药结束时为止，患者治疗的总有效率为87.50%，ＰＡＮＳＳ评分、阳性症状分量表、一般精神病理分量表评分相比于治疗前有了明显的改善(Ｐlt;0.05)，于用药1周末、2周末、3月末、6月末时，均较治疗前的症状有了显著的缓解(Ｐlt;0.01)，阴性症状分量表评分于用药1周后开始下降，至用药结束时，较治疗前有了明显的下降(Ｐlt;0.01)。不良反应轻微多可自行缓解。结论：帕利哌酮缓释片用于儿童期首发精神分裂症患者治疗，起效较快，药效明显，不良反应轻微，服药依从性较好，值得推广使用。 　　【关键词】帕利哌酮缓释片；儿童精神病；首发精神分裂；疗效 　　【中图分类号】R453 【文献标识码】A 【文章编号】2095-1752（2015）09-0049-02 　　Clinical study of childhood schizophrenia treatment Paliperidone Extended-Release Tablets for. Lu Zhixin, Zhang Xia, Shi Le,i Li Zhijia.Mental Health Center of Wuxi City, Jiangsu Province, Wuxi 214151, China 　　【Abstract】Objective: To investigate the paliperidone extended release tablets for the treatment of childhood schizophrenia episode efficacy and advantages and disadvantages of suffering. Methods:A retrospective analysis of 40 cases of childhood Application paliperidone extended release tablets in the treatment of first clinical data of patients with schizophrenia, with its own conditions before and after treatment were compared to evaluate efficacy and adverse reactions 6 months after treatment. Results: At the end of treatment to date, patients treated with total effective rate 87.50%, PANSS score, positive symptoms subscale, general psychopathology subscale score has been significantly improved compared to before treatment (P lt;0.05), in medicine 1 week, 2 weeks, the end of March, when the end of June, compared with pre-treatment of the symptoms have been significantly alleviated (P lt;0.01), negative symptoms subscale scores at 1 week after treatment began to decline, until the end of treatment, compared with treatment former had dropped significantly (P lt;0.01). Adverse reactions were mild and more can relieve itself. Conclusion:paliperidone extended release tablets for the treatment of patie